Revolution Medicines, Inc. — Director's Dealing 2021

Feb 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Revolution Medicines, Inc. (RVMD)
CIK: 0001628171
Period of Report: 2021-02-04

Reporting Person: Weber Barbara (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-04	Common Stock	M	5000	$4.73	Acquired	6808	Direct
2021-02-04	Common Stock	S	4100	$50.0234	Disposed	2708	Direct
2021-02-04	Common Stock	S	900	$51.8567	Disposed	1808	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-04	Stock Option (Right to Buy)	$4.73	M	5000	Disposed	2029-08-08	Common Stock (5000)	Direct

Footnotes

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2: Includes 1,808 Restricted Stock Units.

F3: The transaction was executed in multiple trades in prices ranging from $50.00 to $50.485, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4: The transaction was executed in multiple trades in prices ranging from $51.35 to $51.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F5: This option is early exercisable. One thirtieth (1/30th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date") so that 100% of the shares subject to the option will be fully vested as of two and a half years following the Vesting Commencement Date, subject to the Reporting Person's continued service through each such vesting date.